CompletedPHASE1, PHASE2NCT05105685
Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS
Studying Phelan-McDermid syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Affiliated Hospital of Jiangnan University
- Principal Investigator
- YueYing Liu, PhdAffiliated Hospital of Jiangnan University
- Intervention
- recombinant human growth hormone(drug)
- Enrollment
- 6 enrolled
- Eligibility
- 1-5 years · All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- Affiliated Hospital of JiangNan University, Department of Pediatrics, Wuxi, Jiangsu, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05105685 on ClinicalTrials.govOther trials for Phelan-McDermid syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07281079A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromeNeuren Pharmaceuticals Limited
- RECRUITINGNANCT07014020RB001 Gene Therapy Study in Children With SHANK3-related Phelan McDermid Syndrome (PMS)Peking University First Hospital
- RECRUITINGPHASE1, PHASE2NCT06662188JAG201 Gene Therapy Study in Children & Adults With SHANK3 HaploinsufficiencyJaguar Gene Therapy, LLC
- ACTIVE NOT RECRUITINGNCT02461420Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid SyndromeBoston Children's Hospital